Rematib ( Upadacitinib 15 mg )

Rematib (Upadacitinib 15 mg) is an oral Janus kinase 1 (JAK1) inhibitor designed for the management of chronic inflammatory and autoimmune diseases. It is indicated for patients who have not responded to, cannot tolerate, or have contraindications to conventional treatments such as TNF inhibitors.

Upadacitinib is approved for use in adults and selected pediatric populations for the treatment of:

• Rheumatoid arthritis (RA)

• Psoriatic arthritis (PsA)

• Ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis

• Polyarticular juvenile idiopathic arthritis (PJIA) in children ≥ 2 years

• Atopic dermatitis (eczema) in adolescents and adults

• Ulcerative colitis (moderate to severe)

• Crohn’s disease (moderate to severe)

• Giant cell arteritis

Rematib (Upadacitinib) Dosage：

• Arthritis & spondyloarthritis: 15 mg once daily

• Atopic dermatitis: 15 mg once daily; may increase to 30 mg (adult) if clinically required under supervision

• Ulcerative colitis & Crohn’s disease: induction: 45 mg once daily (limited duration), followed by maintenance 15 mg once daily

• Pediatric: weight-based dosing for PJIA or PsA

Administration guidelines:

• May be taken with or without food

• Swallow tablets whole; do not split, crush, or chew

• Routine clinical monitoring recommended before and during therapy

Upadacitinib Price 

Commercial and patient interest frequently centers on upadacitinib price, upadacitinib cost, and upadacitinib generic availability. Regional pricing inquiries such as upadacitinib cost UK also represent strong demand trends, particularly for chronic long-term therapies. Comparative cost assessments and alternative treatment evaluations are commonly sought for improved affordability and accessibility.

Rematib (Upadacitinib) Side Effects

Upadacitinib may cause mild to moderate side effects, though serious adverse reactions can occur in some patients.

Common side effects include:

• Upper respiratory tract infections (sinusitis, common cold)

• Nausea

• Headache

• Acne or rashes

• Cough, sore throat, nasal symptoms

• Muscle pain

• Weight changes

• Folliculitis

Other reported reactions:

• Fever or chills

• Abdominal discomfort

• Elevated cholesterol levels

Upadacitinib carries boxed warnings. Patients receiving therapy should be assessed and monitored.

Potential serious risks include:

• Serious infections (bacterial, viral, fungal)

• Malignancy risk (e.g., lymphoma)

• Cardiovascular events (heart attack, stroke)

• Venous thromboembolism (VTE)

• Reactivation of tuberculosis or hepatitis

• Severe hypersensitivity reactions

Important considerations:

• Avoid use during pregnancy or breastfeeding without medical guidance

• Live vaccines should generally be avoided

• Laboratory monitoring of CBC, liver function, and lipid levels is recommended